<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="388">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117687</url>
  </required_header>
  <id_info>
    <org_study_id>MAF-AGN-OPH-DE-016</org_study_id>
    <nct_id>NCT02117687</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>France: Institutional Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi
      for the management of dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Global Ocular Staining Score in the Study Eye</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Ocular Staining Score in the Study Eye</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ocular Surface Disease Index© (OSDI) Score</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Schirmer Test in the Study Eye</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Dry Eye Symptoms on a 5-Point Scale</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment of Treatment Efficacy on a 5-Point Scale</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Treatment Acceptability on a 5-Point Scale</measure>
    <time_frame>Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale</measure>
    <time_frame>Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye</measure>
    <time_frame>Baseline, Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment Questionnaire Score</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Corneal Staining in the Study Eye</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Conjunctival Staining in the Study Eye</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperaemia in the Study Eye</measure>
    <time_frame>Baseline, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Product Use</measure>
    <time_frame>Day 8, Day 35, Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of times the study product is administered per day is recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>OPTIVE FUSION™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VISMED® Multi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxymethylcellulose 0.5%/glycerin 0.9%</intervention_name>
    <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
    <arm_group_label>OPTIVE FUSION™</arm_group_label>
    <other_name>OPTIVE FUSION™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium hyaluronate 0.18%</intervention_name>
    <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
    <arm_group_label>VISMED® Multi</arm_group_label>
    <other_name>VISMED® Multi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Use of artificial tears for dry eye in both eyes for at least 3 months

          -  Use of preservative-free artificial tears at least twice daily for 2 weeks;

        Exclusion Criteria:

          -  Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy
             (PRK) surgery in the last 12 months

          -  Use of punctal plugs or contact lenses in the last month

          -  Active ocular allergy within last 2 years

          -  Best corrected visual acuity (BCVA) less than 20/200 in either eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 22, 2016</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <firstreceived_results_date>January 22, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OPTIVE FUSION™</title>
          <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
        <group group_id="P2">
          <title>VISMED® Multi</title>
          <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OPTIVE FUSION™</title>
          <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
        <group group_id="B2">
          <title>VISMED® Multi</title>
          <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Global Ocular Staining Score in the Study Eye</title>
        <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Global Ocular Staining Score in the Study Eye</title>
            <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2" spread="1.11"/>
                  <measurement group_id="O2" value="5.2" spread="1.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.5" spread="1.54"/>
                  <measurement group_id="O2" value="-1.6" spread="1.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Ocular Staining Score in the Study Eye</title>
        <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Global Ocular Staining Score in the Study Eye</title>
            <description>Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.2" spread="1.11"/>
                  <measurement group_id="O2" value="5.2" spread="1.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.5" spread="2.23"/>
                  <measurement group_id="O2" value="-2.4" spread="2.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ocular Surface Disease Index© (OSDI) Score</title>
        <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Ocular Surface Disease Index© (OSDI) Score</title>
            <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.5" spread="22.02"/>
                  <measurement group_id="O2" value="44.4" spread="17.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.3" spread="13.51"/>
                  <measurement group_id="O2" value="-12.9" spread="13.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Schirmer Test in the Study Eye</title>
        <description>The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Schirmer Test in the Study Eye</title>
            <description>The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).</description>
            <units>Millimeters (mm)/5 Minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.1" spread="10.22"/>
                  <measurement group_id="O2" value="8.7" spread="7.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="7.74"/>
                  <measurement group_id="O2" value="1.0" spread="5.44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Dry Eye Symptoms on a 5-Point Scale</title>
        <description>Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Assessment of Dry Eye Symptoms on a 5-Point Scale</title>
            <description>Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline Stinging/Burning - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Stinging/Burning - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Stinging/Burning - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Stinging/Burning - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Stinging/Burning - Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Stinging/Burning - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Stinging/Burning - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Stinging/Burning - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Stinging/Burning - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Stinging/Burning - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Stinging/Burning - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Stinging/Burning - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Stinging/Burning - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Stinging/Burning - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Stinging/Burning - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Itching - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Itching - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Itching - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Itching - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Itching - Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Itching- None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Itching- Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Itching- Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Itching- Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Itching- Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Itching- None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Itching- Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Itching- Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Itching- Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Itching- Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Sandiness/Grittiness - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Sandiness/Grittiness - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Sandiness/Grittiness - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Sandiness/Grittiness - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bsln Sandiness/Grittiness-Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Sandiness/Grittiness - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Sandiness/Grittiness - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Sandiness/Grittiness - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Sandiness/Grittiness - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Sandiness/Grittiness - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Sandiness/Grittiness - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Sandiness/Grittiness - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Sandiness/Grittiness - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Sandiness/Grittiness - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Sandiness/Grittiness - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Blurred Vision - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Blurred Vision - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Blurred Vision - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Blurred Vision - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Blurred Vision - Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Blurred Vision - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Blurred Vision - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Blurred Vision - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Blurred Vision - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Blurred Vision - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Blurred Vision - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Blurred Vision - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Blurred Vision - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Blurred Vision - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Blurred Vision - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Dryness - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Dryness - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Dryness - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Dryness - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Dryness - Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Dryness - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Dryness - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Dryness - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Dryness - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Dryness - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Dryness - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Dryness - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Dryness - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Dryness - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Dryness - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Light Sensitivity - None (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Light Sensitivity - Mild (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Light Sensitivity - Moderate (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Light Sensitivity - Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Light Sensitivity - Very Severe (N=32,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Light Sensitivity - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Light Sensitivity - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Light Sensitivity - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Light Sensitivity - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Light Sensitivity - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Light Sensitivity - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Light Sensitivity - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Light Sensitivity - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Light Sensitivity - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Light Sensitivity - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Painful or Sore - None (N=31,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Painful or Sore - Mild (N=31,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Painful or Sore - Moderate (N=31,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Painful or Sore - Severe (N=31,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Painful or Sore - Very Severe (N=31,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Painful or Sore - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Painful or Sore - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Painful or Sore - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Painful or Sore - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Painful or Sore - Very Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Painful or Sore - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Painful or Sore - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Painful or Sore - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Painful or Sore - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Painful or Sore - Very Severe (N=34,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Other - None (N=3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Other - Mild (N=3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Other - Moderate (N=3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Other - Severe (N=3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Other - Very Severe (N=3,1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Other - None (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Other - Mild (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Other - Moderate (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Other - Severe (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 Other - Very Severe (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Other - None (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Other - Mild (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Other - Moderate (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Other - Severe (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 Other - Very Severe (N=1,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Assessment of Treatment Efficacy on a 5-Point Scale</title>
        <description>Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Global Assessment of Treatment Efficacy on a 5-Point Scale</title>
            <description>Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Day 35 - Much Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - About the Same</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Much Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - About the Same</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Much Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Treatment Acceptability on a 5-Point Scale</title>
        <description>Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).</description>
        <time_frame>Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Assessment of Treatment Acceptability on a 5-Point Scale</title>
            <description>Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Liked - Strongly Agree (N=35,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liked - Agree (N=35,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liked - Neither Agree nor Disagree (N=35,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liked - Disagree (N=35,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liked - Strongly Disagree (N=35,30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Comfortable - Strongly Agree</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Comfortable - Agree</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Comfortable - Neither Agree nor Disagree</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Comfortable - Disagree</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Comfortable - Strongly Disagree</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale</title>
        <description>Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).</description>
        <time_frame>Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale</title>
            <description>Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Day 35 - Very Satisfactory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Satisfactory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Very Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Very Satisfactory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Satisfactory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Very Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye</title>
        <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).</description>
        <time_frame>Baseline, Day 35</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye</title>
            <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).</description>
            <units>Seconds</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.52" spread="2.575"/>
                  <measurement group_id="O2" value="5.75" spread="3.146"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="1.66"/>
                  <measurement group_id="O2" value="0.7" spread="2.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment Questionnaire Score</title>
        <description>The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, who did not adhere to a pre-defined list of protocol violation criteria, and who had data for this data point</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Work Productivity and Activity Impairment Questionnaire Score</title>
            <description>The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline - Work Productivity (N=11,13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.09" spread="1.921"/>
                  <measurement group_id="O2" value="3.46" spread="3.382"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Activity Impairment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.91" spread="2.035"/>
                  <measurement group_id="O2" value="4.35" spread="2.550"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Work Productivity (N=11,9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.55" spread="1.809"/>
                  <measurement group_id="O2" value="2.33" spread="1.936"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Activity Impairment (N=34,31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.09" spread="2.065"/>
                  <measurement group_id="O2" value="3.52" spread="2.393"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Work Productivity (N=11,10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.82" spread="0.982"/>
                  <measurement group_id="O2" value="2.40" spread="2.066"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Activity Impairment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.14" spread="1.630"/>
                  <measurement group_id="O2" value="2.77" spread="2.232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Corneal Staining in the Study Eye</title>
        <description>The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Corneal Staining in the Study Eye</title>
            <description>The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="0.68"/>
                  <measurement group_id="O2" value="1.9" spread="0.65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="0.77"/>
                  <measurement group_id="O2" value="-0.7" spread="0.83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="0.84"/>
                  <measurement group_id="O2" value="-0.9" spread="1.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Conjunctival Staining in the Study Eye</title>
        <description>The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Conjunctival Staining in the Study Eye</title>
            <description>The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline - Temporal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="0.64"/>
                  <measurement group_id="O2" value="1.6" spread="0.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35 - Temporal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="0.66"/>
                  <measurement group_id="O2" value="-0.5" spread="0.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Month 3 - Temporal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="0.79"/>
                  <measurement group_id="O2" value="-0.8" spread="0.92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Nasal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" spread="0.66"/>
                  <measurement group_id="O2" value="1.7" spread="0.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Day 35 - Nasal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="0.65"/>
                  <measurement group_id="O2" value="-0.5" spread="0.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Month 3 - Nasal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="0.97"/>
                  <measurement group_id="O2" value="-0.7" spread="0.87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperaemia in the Study Eye</title>
        <description>Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).</description>
        <time_frame>Baseline, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Conjunctival Hyperaemia in the Study Eye</title>
            <description>Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35 - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Trace</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 - Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Product Use</title>
        <description>The number of times the study product is administered per day is recorded.</description>
        <time_frame>Day 8, Day 35, Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol: all randomized subjects who received at least one dose of the study product, had at least one follow-up visit, and who did not adhere to a pre-defined list of protocol violation criteria</population>
        <group_list>
          <group group_id="O1">
            <title>OPTIVE FUSION™</title>
            <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>VISMED® Multi</title>
            <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Study Product Use</title>
            <description>The number of times the study product is administered per day is recorded.</description>
            <units>Number of Times/Day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.63" spread="1.190"/>
                  <measurement group_id="O2" value="3.47" spread="0.900"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 35</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.77" spread="1.285"/>
                  <measurement group_id="O2" value="3.39" spread="0.761"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.71" spread="1.178"/>
                  <measurement group_id="O2" value="3.42" spread="0.958"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population included all randomized subjects treated with at least one dose of study product. The Safety Population was used to assess adverse events (AEs) and serious adverse events (SAEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>OPTIVE FUSION™</title>
          <description>1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
        <group group_id="E2">
          <title>VISMED® Multi</title>
          <description>1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
